{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:22:13Z","timestamp":1781112133731,"version":"3.54.1"},"reference-count":24,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Super responders (SRs)\u2014patients achieving complete skin clearance (PASI = 0) soon after biologic initiation\u2014represent a clinically relevant but underexplored phenotype. This study is one of the first real-world, multi-agent analyses comparing SR likelihood across biologic classes in plaque psoriasis. We assessed whether biologic choice predicts SR in routine clinical practice. Methods: We performed a retrospective, single-center study of 116 adults with moderate-to-severe plaque psoriasis initiating their first biologic (adalimumab, tildrakizumab, guselkumab, risankizumab, bimekizumab, or secukinumab). SR was defined as PASI = 0 at week 12. SR proportions (exact 95% CIs) were compared using Fisher\u2019s exact tests and odds ratios (ORs). Multivariable logistic regression estimated adjusted associations between biologic and SR, controlling for age, sex, disease duration, BMI, baseline PASI, and prior cyclosporine\/acitretin. Sensitivity analyses included Firth bias-reduced regression, the exclusion of sparse drug strata, and an alternative endpoint (PASI \u2264 1 at week 12). Results: Overall, 26\/116 patients (22.4%) achieved SR. SR proportions differed by agent, highest with bimekizumab (11\/17; 64.7%); Fisher\u2019s p &lt; 0.001 vs. others; OR = 12.83 (95% CI 4.17\u201339.50). In adjusted models, bimekizumab remained independently associated with SR (adjusted OR = 17.30; 95% CI 4.62\u201364.82; p = 2.35 \u00d7 10\u22125), while other covariates were not significant. Conclusions: In this real-world cohort, biologic selection\u2014particularly bimekizumab\u2014was the main determinant of early complete clearance. These findings highlight mechanistic class as a key driver of rapid, deep responses and support prospective validation with harmonized SR definitions and extended follow-up.<\/jats:p>","DOI":"10.3390\/jcm14207293","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:39:34Z","timestamp":1760701174000},"page":"7293","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Super Responders in Plaque Psoriasis: A Real-World, Multi-Agent Analysis Showing Bimekizumab Associated with the Highest Odds of PASI = 0 at Week 12"],"prefix":"10.3390","volume":"14","author":[{"given":"Dominika","family":"Ziolkowska-Banasik","sequence":"first","affiliation":[{"name":"Clinical Department of Dermatology, Medical University of Silesia, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Zawadzinska-Halat","sequence":"additional","affiliation":[{"name":"Clinical Department of Dermatology, Medical University of Silesia, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Basta","sequence":"additional","affiliation":[{"name":"Clinical Department of Dermatology, Medical University of Silesia, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7241-9685","authenticated-orcid":false,"given":"Maciej","family":"Pastuszczak","sequence":"additional","affiliation":[{"name":"Clinical Department of Dermatology, Medical University of Silesia, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"adv42945","DOI":"10.2340\/actadv.v105.42945","article-title":"Epidemiology of Psoriasis: A Worldwide Global Study","volume":"105","author":"Skayem","year":"2025","journal-title":"Acta Derm. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hu, S.C.-S., and Lan, C.-C.E. (2017). Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102211"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","article-title":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis","volume":"82","author":"Warren","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/24755303211047479","article-title":"TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: Therapeutic utility in the era of IL-17 and IL-23 inhibitors","volume":"7","author":"Hong","year":"2022","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamadermatol.2023.6236","article-title":"Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis","volume":"160","author":"Egilman","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_6","first-page":"1366","article-title":"Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab","volume":"25","author":"Blauvelt","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\u201cSuperresponders\u201d at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/PTT.S514249","article-title":"Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events","volume":"15","author":"Fratton","year":"2025","journal-title":"Psoriasis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Reich","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: A nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s13555-025-01394-2","article-title":"Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study","volume":"15","author":"Mortato","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","article-title":"Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation","volume":"43","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s13555-025-01494-z","article-title":"Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)","volume":"15","author":"Pinter","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ziolkowska-Banasik, D., Pastuszczak, M., Zawadzinska-Halat, K., Hadas, E., and Bozek, A. (2025). Serum IL-18\/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.1120.v1"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Marcelli, L., Belcastro, A., Talamonti, M., Paganini, C., Fico, A., Savastano, L., Di Raimondo, C., Vellucci, L., Bianchi, L., and Galluzzo, M. (2024). Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175175"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/ijd.15784","article-title":"Super responders to guselkumab treatment in moderate-to-severe psoriasis: A real clinical practice pilot series","volume":"61","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Narcisi, A., Ibba, L., Balato, A., Bianchi, L., Brianti, P., Buononato, D., Burlando, M., Caldarola, G., and Campanati, A. (2023). Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: A real-life multicenter study\u2014IL PSO (Italian Landscape Psoriasis). Front. Med., 10.","DOI":"10.3389\/fmed.2023.1243843"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13555-025-01361-x","article-title":"Indirect comparison between bimekizumab and brodalumab for the management of moderate-to-severe psoriasis: A 36-week real-life study","volume":"15","author":"Potestio","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40261-025-01440-z","article-title":"Super responder profile under bimekizumab treatment in moderate-to-severe psoriasis: A short-term real-life observation\u2014IL PSO (Italian Landscape Psoriasis)","volume":"45","author":"Esposito","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2147\/TCRM.S338661","article-title":"Once-daily abrocitinib for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and over: A short review of current clinical perspectives","volume":"18","author":"Niculet","year":"2022","journal-title":"Ther. Clin. Risk Manag."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:12:53Z","timestamp":1760703173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":24,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14207293"],"URL":"https:\/\/doi.org\/10.3390\/jcm14207293","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}